Dr. Lachowiez is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3181 SW Sam Jackson Park Rd
Portland, OR 97239Phone+1 503-494-5058Fax+1 503-494-5065
Education & Training
- University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2019 - 2022
- University of Nebraska College of MedicineClass of 2015
Certifications & Licensure
- OR State Medical License 2017 - 2025
- TX State Medical License 2020 - 2024
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Inductee Alpha Omega Alpha Honor Medical Society
Publications & Presentations
PubMed
- 1 citationsThromboprophylaxis with intermediate dose enoxaparin during asparaginase containing induction for young adults with acute lymphoblastic leukemia.Hong De Sa, Thomas Deloughery, Andy Kaempf, Curtis Lachowiez, Jessica Leonard
Leukemia & Lymphoma. 2025-01-01 - 1 citationsRefined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML.Curtis A Lachowiez, Vishvaas I Ravikumar, Jad Othman, Jenny O'Nions, Daniel T Peters
Blood. 2024-12-26 - Clinical Outcomes of Patients With Newly Diagnosed Acute Myeloid Leukemia Receiving Treatment in a Safety-Net Hospital System.Jason Lu, Preeya Bhakta, Hyunsoo Hwang, Curtis Lachowiez, Effrosyni Apostolidou
Clinical Lymphoma, Myeloma & Leukemia. 2024-12-21
Press Mentions
- ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2024October 24th, 2024
- ORYZON Announces First Patient Dosed in an Investigator-Initiated Phase Ib Study of Iadademstat in First-Line Acute Myeloid LeukemiaSeptember 9th, 2024
- Determining the Optimal Frontline Treatment of AMLDecember 6th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: